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Antimycobacterial and cytotoxicity activity of synthetic and natural compounds. Secondary metabolites from Curvularia eragrostidis
and Drechslera dematioidea, Clusia sp. floral resin, alkaloids from Pilocarpus alatus, salicylideneanilines, piperidine amides, the
amine 1-cinnamylpiperazine and chiral pyridinium salts were assayed on Mycobacterium tuberculosis H37Rv. N-(salicylidene)-2-
hydroxyaniline was the most effective compound with a minimal inhibitory concentration (MIC) of 8 µmol/L. Dihydrocurvularin was
moderately effective with a MIC of 40 μmol/L. Clusia sp. floral resin and a gallocatechin-epigallocatechin mixture showed MIC of
0.02 g/L and 38 µmol/L, respectively. The cytotoxicity was evaluated for N-(salicylidene)-2-hydroxyaniline, curvularin, dihydrocurvularin
and Clusia sp. floral resin, and the selectivity indexes were > 125, 0.47, 0.75 and 5, respectively.
Keywords: antimycobacterial activity; natural products; synthetic products.
INTRODUCTION
After AIDS, tuberculosis (TB) is the leading cause of infectious
disease mortality in the world entering the 21st century. The
emergence of multi-drug resistant Mycobacterium tuberculosis
strains is a contributing factor to the urgent need for new and more
effective antimycobacterial drugs. In this context, many groups are
fully committed to finding good active drugs that kill bacilli with
low toxicity to mammalians1.
One of the oldest and most effective strategies to discover and
develop new chemotherapeutics is to conduct bioassays of the crude
extract of natural products before isolating and evaluating its
chemical components. Secondary metabolites from plants and
microorganisms represent a large source of compounds endowed
with ingenious structures and potent biological activities. Many of
the products currently used on humans or for animal therapy in
animal husbandry and in agriculture are produced by microbial
fermentation or derived from the chemical modification of a natu-
ral product2.
In the field of synthetic chemistry, numerous studies of the
synthesis and antimicrobial characteristics of quaternary ammonium
compounds have been conducted since 1935. Among these
compounds, pyridinium salts represent an important group of
chemicals widely used as biocides, cationic surfactants, drugs and
herbicides. Disinfectants based on this class are widely used in
hospital environments and in the food industry due to their low
toxicity to humans and animals and to their wide antimicrobial
spectra3. A class of functionalized cationic surfactants showed
antimicrobial activity with some exhibiting strong activities over
wide antibacterial spectra similar to the activity of benzalkonium
chlorides4.
This study, in a continuing effort to seek effective antimyco-
bacterial substances5-7, reports the determination of the minimal
inhibitory concentration (MIC) for M. tuberculosis H37Rv of a
diverse group of compounds, including N-(salicylidene)-4-toluidine
(1), N-(salicylidene)-2-hydroxyaniline (2), N-(salicylidene)-4-
aminobenzoic acid (3), N-(salicylidene)-4-nitroaniline (4),
dihydrobenzoxazine (5), piperidine amides (6-7), the amine 1-
cinnamylpiperazine (8), a series of chiral pyridinium salts (16-23),
major secondary metabolites from filamentous fungi such as
Curvularia eragrostidis and Drechslera dematioidea, benzophenone
rich floral resin of Clusia sp., and major alkaloids from Pilocarpus
species (24-31). Cellular viability was evaluated for N-(salicylidene)-
2-hydroxyaniline (2), curvularin (28), dihydrocurvularin (29) and
Clusia sp. floral resin.
EXPERIMENTAL
Synthetic compounds
Salicylideneanilines, piperidine amides and amines
The N-(salicylidene)-4-toluidine (1), N-(salicylidene)-2-
hydroxyaniline (2), N-(salicylidene)-4-aminobenzoic acid (3) and
N-(salicylidene)-4-nitroaniline (4) were prepared according to
Iskander and Andrews8, Zheglova et al.9, Senier and Shepeard10,
and Katritsky et al.11, respectively. The dihydrobenzoxazine (5) was
prepared according to Iskander and Andrews8. The amides 3,4-
methylenedioxycinnamoylpiperidine (6) and 3,4-methylenedioxy-
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benzoylpiperidine (7) were obtained through standard procedures12
and the amine 1-cinnamylpiperazine (8) was purchased from Isochem
(Figure 1).
Pyridinium salts
Chiral pyridinium salts (16-23) were prepared via Zincke’s
reaction13 as outlined in Scheme 1. The Zincke’s salts (13), (14)
and (15) were easily prepared via a reaction of commercially
available pyridine (9), 3-picoline (10), and 3-ethylpyridine (11),
respectively, with 1-chloro-2,4-dinitro-benzene (12) under acetone
reflux over 15 h. The treatment of these salts in an equimolar ratio
with selected chiral primary amines in butanol reflux overnight
furnished the corresponding chiral pyridinium salts. The reaction
proceeded without racemization and the salts were isolated as
viscous oils with yields of at least 80% after chromatography on
silica gel. The salt (22) was prepared by treatment of (21) with
sodium dodecyl sulphate in dichloromethane under reflux for 3
hours followed by filtration (Scheme 1).
Physical chemical characterization
Synthesized and isolated compounds were characterized through
physical chemical analysis such as 1H and 13C nuclear magnetic
resonance (NMR), mass spectrometry and infrared spectra, and the
data are in agreement with the literature for the N-(salicylidene)-4-
toluidine (1)8, N-(salicylidene)-2-hydroxyaniline (2)9, N-(salicylidene)-
4-aminobenzoic acid (3)10, N-(salicylidene)-4-nitroaniline (4)11,
dihydrobenzoxazine (5)8, 3,4-methylenedioxycinnamoylpiperidine (6)12,
3,4-methylenedioxybenzoylpiperidine (7)12, 1-(2’,4’-dinitrophenyl)-
pyridinium chloride (13)14, 1-(2’,4’-dinitrophenyl)-3-ethylpyridinium
chloride (14)14, 1-(2’,4’-dinitrophenyl)-3-methylpyridinium chloride
(15)13, (R)-(-)-1-(2’-hydroxy-1’-phenylethyl)-3-ethylpyridinium chloride
(17)14, (S)-(-)-1-(1’-phenylethyl)-3-ethylpyridinium chloride (18)13, (R)-
(-)-1-(2’-hydroxy-1’-phenylethyl)-3-methylpyridinium chloride (20)13,
(S)-(-)-1-(1’-phenylethyl)-3-methylpyridinium chloride (21)15, and (R)-
(-)-1-(2’-hydroxy-1’-phenylethyl)pyridinium chloride (23)14. The data




200 MHz), δ: 1.33 (t, J = 7,5 Hz, 3 H); 2.26 (d, J
= 6,9 Hz, 3 H); 2.97 (q, J = 7,5 Hz, 2 H); 6.77 (q, J = 6.9 Hz, 1 H);
7.37-7.56 (m, 3 H); 8.00 (d, J = 7,3 Hz, 1 H); 8.17 (dd, J = 5.9 Hz,
J = 7.9 Hz, 1 H); 8.32 (d, J = 7.9 Hz, 1 H); 9,25 (d, J = 5.9 Hz, 1 H);
9.37 (s, 1 H) [α]
D
: -69,9 (c=1.32 - EtOH). IR (cm-1): 3350; 3050;
1660; 1630; 1500; 1475; 1450; 1390; 1260; 1200; 1140; 1040; 830;
770; 750; 690.
(S)-(-)-1-[1’(2-chlorophenyl)ethyl]-)-3-methylpyridinium chloride
(19) 1H NMR (CDCl
3, 
200 MHz), δ: 2.25 (d, J = 7.0 Hz, 3 H); 2.64
(s, 3 H); 6.74 (q, J = 7.0 Hz, 1 H); 7.37-7.56 (m, 3 H); 8.00 (d, J =
7.4 Hz, 1 H); 8.13 (dd, J = 6.2 Hz, J = 7.8 Hz, 1 H); 8.32 (d, J = 7.8
Hz, 1 H); 9.22 (d, J = 6.2 Hz, 1 H); 9.42 (s, 1 H).13C NMR (50,3
MHz, CDCl
3
), δ (ppm): 18.6, 21.1, 67.7, 128.0, 128.1, 129.5, 130.3,
131.5, 133.0, 134.6, 139.0, 141.1, 143.3, 146.1. [α]
D
: -19,2o (c=1,14
- EtOH). IR (cm-1): 3350; 3050; 1660; 1630; 1500; 1475; 1450; 1390;
1260; 1200; 1140; 1040; 830; 770; 750; 690.
(S)-(-)-1-(1’-phenylethyl)-3-methylpyridinium dodecyl sulphate (22)
1H NMR (CDCl
3, 
200 MHz), δ:  0.84-0.91 (m, 3 H); 1.23 (s, 18 H);
1.53-1.64 (m, 2 H); 2.52 (s, 3 H); 3.97 [m, 3 H]; 4.29 (dd, J = 4,1
Hz, J = 12,7 Hz, 1 H); 4.54 (dd, J = 9,7 Hz, J = 12,7 Hz); 6.17 (dd,
J = 4,1 Hz, J = 9.7 Hz, 1 H); 7.30-7.38 (m, 3 H); 7.49-7.54 (m, 2 H);
7.92 (dd, J = 6.7 Hz, J = 7.8 Hz, 1 H); 8.11 (d, J = 7.8 Hz, 1 H); 8.91
(s, 1 H); 8.92 (d, J = 6,7 Hz, 1 H) .13C NMR (50,3 MHz, CDCl
3
), δ
14.2, 18.7, 22.8, 25.9, 29.4, 29.6, 29.7, 32.0, 62.5, 68.1, 76.1, 127.9,
128.5, 129.7, 130.2, 133.8, 139.8, 141.6, 141.7, 143.7, 146.3. IR
(cm-1): 3350; 3050; 1660; 1500; 1475; 1390; 1260; 1200; 1040; 830;
770; 750; 690.
Natural products
Leaves of Pilocarpus alatus were collected at Merck Co.’s farm,
in Barra do Corda, Maranhão State, in the Northeast of Brazil. A
voucher specimen (number 35148) was deposited at the Prisco
Bezerra Herbarium (EAC), Universidade Federal do Ceará, Brazil.
The aqueous residue obtained after essential oil extraction of the
leaves (250.0 g) from P. alatus was filtered and lyophilized, and yielded
an aqueous extract, denominated extract 1 (31.0 g). An aliquot (4.8 g)
of this extract was submitted to silica-gel column chromatography
using a gradient mixture of ethyl acetate and methanol; it was then
submitted to exclusion chromatography on Sephadex LH-20 using
methanol as eluent and provided a mixture of gallocatechin (24) and
Figure 1. Structures of synthetic compounds evaluated on M. tuberculosis
H37Rv: N-(salicylidene)-4-toluidine (1), N-(salicylidene)-2-hydroxyaniline (2),
N-(salicylidene)-4-aminobenzoic  acid   (3),  N-(salicylidene)-4-nitroaniline
(4),  dihydrobenzoxazine  (5), 3,4-methylenedioxycinnamoylpiperidine (6),  3,4-
methylenedioxybenzoylpiperidine (7) and 1-cinnamylpiperazine (8)
Scheme 1. Synthesis of chiral pyridinium salts evaluated on M. tuberculosis
H37Rv
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epigallocatechin (25) (2:1) (22.0 mg) as well as the compound rutin
(26) (20.0 mg) (Figure 2). Extract 1 (31.0 g) was partitioned with ethyl
acetate and yielded the extract 2 (5.1 g).
Leaves (400.0 g) of P. alatus were also extracted with hexane
and then with ethanol providing hexane (26.0 g) and ethanolic
extracts (77.0 g), respectively. An aliquot (10.0 g) of the ethanolic
extract, denominated extract 3, was chromatographed on silica gel
by elution with hexane, chloroform, ethyl acetate, acetone and
methanol. The methanol fraction was submitted to successive
chromatographic processes allowing the isolation of hesperidin (27)
(26.0 mg) (Figure 2). Structures of the isolated compounds were
identified through 1H and 13C nuclear magnetic resonance (NMR)
analysis, followed by literature comparison16-19.
Curvularin (28), dihydrocurvularin (29) and cochlioquinone A
(30) were isolated from pure cultures of C. eragrostidis and D.
dematioidea as previously described20. Floral resin of Clusia sp.
rich in benzophenones was obtained as previously described21.
Piperine (27) was isolated from black pepper (Piper nigrum) and
identified as previously described22-24 (Figure 2).
Antimycobacterial activity
The antimycobacterial activity of the samples (compounds 1-
8, 14-31, Clusia sp. floral resin, extract (2 and 3) was assayed in
vitro against M. tuberculosis H37Rv (ATCC 27294) using the
microplate Alamar Blue assay25. Crude extracts, fractions or isolated
compounds were dissolved in dimethylsulphoxide (DMSO) and
serially diluted in Middlebrook 7H9 broth before inoculation.
Concentrations used ranged from 0.5 to 1,000 μmol/L for isolated
compounds and from 0.5 to 1.0 g/L to crude extracts. The final
concentration of DMSO in the assay was less than 0.3%. Rifampicin
was used as reference drug, and bioassays were performed in three
independent experiments. The visual MIC were defined as the lowest
drug concentration inhibiting mycobacterial growth and expressed
by the average of the assays.
Cytotoxicity
The cytotoxic effect was assayed on J774 macrophages through
the reduction of 3-(4,5-dimethylthiazole-2-yl)-2,5-diphenyl
tetrazolium bromide (MTT)26,27. Stock solutions of N-(salicylidene)-
2-hydroxyaniline (2), curvularin (28), dihydrocurvularin (29) and
Clusia sp. floral resin were prepared in DMSO and diluted in RPMI
1640 medium without phenol red. The final concentration of the
solvent in the assay was less than 0.3%. The controls received no
drugs and each drug concentration was tested on six replicates, and
repeated three times in separate experiments. Cells were exposed
to the drugs at concentrations up to 1,000 μmol/L for isolated
compounds (or 1,0 g/L in the case of Clusia sp. floral resin). The
results are expressed by the cellular viability of the cells treated
with the drugs and controls and IC
50
 was defined as the drug
concentration required to reduce cellular viability by 50%. The
cytotoxicity was not evaluated on other sample.
Selectivity indexes (SI=IC
50
/MIC) were calculated for N-
(salicylidene)-2-hydroxyaniline (2), curvularin (28), dihydro-
curvularin (29), and Clusia sp. floral resin.
RESULTS AND DISCUSSION
The MICs were determined in vitro for M. tuberculosis H37Rv.
The most effective compound among tested samples was N-
(salicylidene)-2-hydroxyaniline (2) with a MIC of 8 μmol/L,
followed by dihydrocurvularin (29), dihydrobenzoxazine (5),
piperine (31), cochlioquinone A (30), N-(salicylidene)-4-toluidine
(1), piperidine amide (6) and curvularin (28), which showed MIC
of 40, 250, 250, 250, 500, 500 and 642 μmol/L, respectively.
Zincke’s salts 14 and 15 showed MIC of 807 and 845 μmol/L and
for Clusia sp. floral resin the MIC was 0.02 g/L.
Although ineffective on Aspergillus niger, Staphylococcus
aureus and on Bacillus subtilis as previously reported20,
dihydrocurvularin (29) was moderately effective on M. tuberculosis
with MIC of 40 μmol/L.
Previously, several pyridinium chlorides were evaluated in vitro




methylamino] pyridinium chloride, were tested against M.
tuberculosis H37Rv and showed a MIC of 14 μmol/L. However, in
this study, the antimycobacterial effect of pyridinium salts was shown
to be weak. Pyridinium salt 23 showed a MIC of 1,000 μmol/L while
compounds 16-22 were ineffective with MIC above 1,000 μmol/L.
Similarly, cinnamylpiperazine (8) presented a MIC of 1,000 μmol/L
and N-(salicylidene)-4-aminobenzoic acid (3) and N-(salicylidene)-
4-nitroaniline (4) showed a MIC above 1,000 μmol/L.
Natural compounds, gallocatechin/epigallocatechin mixtures
(2:1) (24 and 25), rutin (26) and hesperidin (27) were unable to
inhibit mycobacteria growth at the tested concentrations of 38, 77
and 77 μmol/L, respectively. The same effect was observed with
extracts 2 and 3 at 0.125 g/L.
Due to their surfactant properties pyridinium salts can be
absorbed by the bacterial cell surface, promoting lyses through
interference with enzymes of the cell wall and membrane3. Although
M. tuberculosis has a lipophilic membrane, pyridinium salts were
ineffective, which suggests that the mechanistic pathways are not
related to the cell wall and membrane.
The most effective synthetic compound on M. tuberculosis was
N-(salicylidene)-2-hydroxyaniline (2), and among the natural
products Clusia sp. floral resin and dihydrocurvularin (29) were
the most effective. It is interesting to note the presence of phenolic
groups in all those most active compounds.
The cellular viability was evaluated through a cytotoxicity assay
for N-(salicylidene)-2-hydroxyaniline (2), curvularin (28),
Figure 2. Structures of natural products evaluated on M. tuberculosis H37Rv:
gallocatechin (24), epigallocatechin (25), rutin (26), hesperidin (27), curvularin
(28), dihydrocurvularin (29), cochlioquinine A (30) and piperine (31).
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dihydrocurvularin (29), and Clusia sp. floral resin. The IC
50
 values
were > 1,000, 300 and 30 μmol/L and 0.1 g/L, respectively. The
cytotoxicity was not evaluated for other samples since they showed
weak antimycobacterial activities with high MIC values.
Previous reports indicated that the drug’s SI above 10 is an
indication of its therapeutic safety and effectiveness for it to be a
good candidate against tuberculosis. The SI values of N-
(salicylidene)-2-hydroxyaniline (2), curvularin (28), dihydro-
curvularin (29) and Clusia sp. floral resin are > 125.0, 0.47, 0.75
and 5.0, respectively. Compound 2 showed a weak cytotoxicity to
J774 macrophages and at 1,000 μmol/L 80% of cells were viable
indicating a higher selectivity of the drug to the pathogen than to
the mammalian cells.
CONCLUSIONS
Among tested samples N-(salicylidene)-2-hydroxyaniline (2)
was the most effective compound on M. tuberculosis H37Rv while
showing a very weak cytotoxicity on J774 macrophages. Its SI is
above 125.0 and at the tested concentration, an IC
50
 was not found
(SI= >1,000/8). The results for this compound are indicative of the
promising antimycobacterial activity of this molecule which, in a
next step, will be tested on experimental tuberculosis.
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